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Camelpox virus (CMLV) gene 176R encodes a protein with sequence similarity to murine schlafen
(m-slfn) proteins. In vivo, short and long members of the m-slfn family inhibited T-cell
development, whereas in vitro, only short m-slfns caused arrest of fibroblast growth. CMLV 176
protein (v-slfn) is most closely related to short m-slfns; however, when expressed stably in
mammalian cells, v-slfn did not inhibit cell growth. v-slfn is a predominantly cytoplasmic 57 kDa
protein that is expressed throughout infection. Several other orthopoxviruses encode v-slfn
proteins, but the v-slfn gene is fragmented in all sequenced variola virus and vaccinia virus
(VACV) strains. Consistent with this, all 16 VACV strains tested do not express a v-slfn detected
by polyclonal serum raised against the CMLV protein. In the absence of a small animal model to
study CMLV pathogenesis, the contribution of CMLV v-slfn to orthopoxvirus virulence was
studied via its expression in an attenuated strain of VACV. Recombinant viruses expressing
wild-type v-slfn or v-slfn tagged at its C terminus with a haemagglutinin (HA) epitope were less
virulent than control viruses. However, a virus expressing v-slfn tagged with the HA epitope at its
N terminus had similar virulence to controls, implying that the N terminus has an important
function. A greater recruitment of lymphocytes into infected lung tissue was observed in the
presence of wild-type v-slfn but, interestingly, these cells were less activated. Thus, v-slfn is an
orthopoxvirus virulence factor that affects the host immune response to infection.
INTRODUCTION
Camelpox virus (CMLV) is a member of the genus Ortho-
poxvirus (OPV) of the family Poxviridae, a group of
large double-stranded DNA viruses that replicate in the
cytoplasm (Moss, 2001). Compared with other OPVs,
CMLV is poorly characterized. The genomes of CMLV
strains CMS (Gubser & Smith, 2002) and M-96 (Afonso
et al., 2002) were sequenced and revealed that CMLV is
genetically closely related to variola virus (VARV), the
cause of smallpox (Gubser & Smith, 2002). Like other
OPVs, the CMLV genome has a highly conserved central
region of about 100 kb encoding genes that are mostly
essential for virus replication. In contrast, the genome
termini encode proteins known or predicted to affect virus
virulence or modulation of the host’s immune response.
Among these terminal genes, CMLV strain CMS 176R
encodes a protein with sequence similarity to mammalian
schlafens (slfn) (Gubser & Smith, 2002).
The prototypic member of the slfn family, murine (m-)
slfn1, was discovered by a subtractive hybridization be-
tween transgenic mice in which T-cell maturation was
halted at the CD4
+8
+ double-positive stage and mice in
which maturation was skewed toward CD4 single-positive
selection (Schwarz et al., 1998). BLAST searches identified a
further eight related mouse genes that are classified as short
(slfn1 and 2), intermediate (slfn3 and 4) or long (slfn5, 8, 9,
10 and 14) m-slfns, depending on their size (Schwarz et al.,
1998; Geserick et al., 2004) (Fig. 1). All m-slfns share a
conserved region that contains a putative divergent ATPase
associated with the cellular activities (AAA) domain (Lupas
& Martin, 2002; Frickey & Lupas, 2004), whereas inter-
mediate and long m-slfns have additional C-terminal
sequences. In vivo, short and long m-slfns inhibit T-cell
development (Schwarz et al., 1998; Geserick et al., 2004),
whereas in vitro, only m-slfn1 caused arrest of fibroblast
growth by inhibition of cyclin D1 (Schwarz et al., 1998;
Geserick et al., 2004; Brady et al., 2005). Additionally, the
expression level of m-slfns is regulated differentially after
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et al., 2003) and Listeria (Geserick et al., 2004), suggesting a
role in host defence against pathogens.
This study describes the characterization of CMLV strain
CMS slfn-like protein 176 (v-slfn). Bioinformatic analyses
showed that v-slfn is most closely related to short m-slfns.
However, unlike m-slfn1, v-slfn did not inhibit cell growth
when expressed stably in mammalian cells. Using specific
antiserum, we showed that v-slfn is a predominantly cyto-
plasmic 57 kDa protein that is expressed throughout
infection. Screening of 18 OPVs showed that immunologi-
cally related proteins of similar sizes are expressed by two
cowpox virus (CPXV) strains but not by any of the 16
vaccinia virus (VACV) strains tested. To address whether
v-slfn affected OPV virulence, CMLV v-slfn was expressed
from the thymidine kinase (TK) locus of an attenuated
VACV strain. In vivo, this recombinant virus was attenuated
further compared with controls, and induced different
recruitment of lymphocytes to the site of infection.
METHODS
Cells and viruses. BS-C-1, TK
2143 and HeLa cells were grown at
37uCi na5 %C O 2 atmosphere in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% heat-inactivated fetal
bovine serum (FBS; Gibco), 100 U penicillin ml
21 (Gibco) and
100 mg streptomycin ml
21 (Gibco). The source of VACV strain
Western Reserve (WR) vDB8R and CMLV strain CMS was described
previously (Gubser & Smith, 2002; Symons et al., 2002).
Viral growth curves. The one-step growth kinetics of VACV strains
were determined as described previously (Pires de Miranda et al.,
2003).
Plasmids. CMLV strain CMS genomic DNA was used for PCR-
mediated amplification of the v-slfn gene. For construction of recom-
binant viruses, haemagglutinin (HA)-tagged or wild-type (WT) v-slfn
were cloned into pMJ601 (Davison & Moss, 1990) to create plasmids
pMJ601-176RWT, pMJ601-176RNHA and pMJ601-176RCHA. Oligo-
nucleotide primers were forward primers 176FW (59-CCCCCG-
CTCGAGGCCGCCACCATGGCGATGTTTTACGCACACGC-39)
and 176FH (59-CCCCCGCTCGAGGCCGCCACCATGTACCCATA-
CGATGTTCCAGATTACGCTGCGATGTTTTACGCACACGC-39),
Fig. 1. CMLV v-slfn is related to members of
the mammalian slfn family. (a) Diagrammatic
representation of CMLV strain CMS v-slfn
(GenBank accession no. AAG37679), VACV-
WR B2 (YP_233066) and B3 (YP_233067),
and murine slfns m-slfn1 (AAH52869),
m-slfn3 (NP_035539) and m-slfn8 (NP_
853523). Protein sizes (number of aa) are
shown on the right. (b) CLUSTAL W (Thompson
et al., 1994) alignment of the m-slfn1, 3 and 8
conserved region with the C terminus of v-slfn.
Identical residues are shown in black and
residues conserved in two or three out of four
sequences are shown in light or dark grey,
respectively. Amino acid co-ordinates are
indicated. (c) Unrooted phylogenetic tree
showing the relationship of v-slfn from camel-
pox virus (CMLV), cowpox virus (CPXV),
monkeypox virus (MPXV), ectromelia virus
(ECTV), taterapox virus (GBLV) and m-slfns.
Protein sequences were aligned using CLUSTAL
W and an unrooted tree was generated based
on this alignment using PHYLIP on the European
Bioinformatic Institute website (http://www.e-
bi.ac.uk/clustalw/). Bootstrap values from
1000 replica samplings and the divergence
scale (substitutions per site) are indicated.
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TTATAGATGACACCC-39) and 176RH (59-CGCCGCCCCGGGTT-
AAGCGTAATCTGGAACATCGTATGGGTAAAATTTTATAGATG-
ACACCC-39); restriction sites for XhoI and SmaI, respectively, are
underlined. The influenza virus A/34/PR/8 HA gene was subcloned
from plasmid pGS63 (Smith et al., 1987) into pMJ601 to create
plasmid pMJ601-H1. For bacterial expression, the v-slfn gene was
cloned into the pET28a vector (Novagen) without the stop codon to
obtain a C-terminal histidine (His) tag, creating pET28-176CHis.
Oligonucleotide primers were 176FB (59-CCCCCCCATGGCGATG-
TTTTACGCACACGC-39) and 176RB (59-CCCCCCTCGAGAAAT-
TTTATAGATGACACCC-39); restriction sites for NcoI and XhoI,
respectively, are underlined. For production of stable cell lines, the v-
slfn gene encoding a C-terminal FLAG tag was cloned into the T-REx
tetracycline-inducible expression vector pcDNA4/TO (Invitrogen)
creating pcDNA4/TO-v-slfn-FLAG. Oligonucleotide primers were
CMLV176 forward (59-CGCTCTAGAATGGCGATGTTTTACGCA-
39) and CMLV176 reverse (5-CCCAAGCTTTTACTTGTCGTCGTC-
GTCCTTGTAGTCAAATTTTATAGATGACAC-39). Underlined and
bold nucleotides represent the restriction site for HindIII and FLAG
tag, respectively. The fidelity of all PCR-generated DNA sequences was
confirmed by sequencing.
Generation of v-slfn tetracycline-inducible stable cells. NIH3T3
murine fibroblasts were transfected with linearized pcDNA4/TO-v-
slfn-FLAG and pcDNA6/TR vectors (Invitrogen) and cell lines were
selected under antibiotic selection with 3 mg blasticidin ml
21 and
750 mg zeocin ml
21 for 3 weeks. Clone B7 was selected as the line
exhibiting no basal v-slfn expression and the highest tetracycline
inducibility.
Production of rabbit polyclonal antiserum to v-slfn. Plasmid
pET28-176CHis was transformed into Rosetta-gami Escherichia coli
cells (Novagen) and cultured in Luria–Bertani (LB) medium at 37uC
until the OD600 reached 0.6. Protein expression was induced by the
addition of 1 mM IPTG for 3 h at 37uC. Cells were lysed in
BugBuster protein extraction reagent (Novagen) containing protease
inhibitor cocktail set III (Calbiochem). The bacterial lysates were
sonicated and the insoluble material was removed by centrifuga-
tion at 10000 g for 10 min. v-slfn was purified from insoluble
inclusion bodies by washing four times in wash buffer (20 mM
Tris pH 7.5, 10 mM EDTA, 1% Triton X-100). SDS-PAGE and
Coomassie blue staining confirmed that v-slfn was the major
protein present (data not shown). A polyclonal rabbit antiserum
was raised against v-slfn by Harlan Seralabs. To reduce cross-
reactivity of the antiserum with denatured mammalian proteins,
the antiserum was incubated with HeLa cell proteins. HeLa cells
(3610
8) were lysed using acetone and proteins were collected by
centrifugation and dried overnight at room temperature. Antiserum
diluted 1:10 in PBS was added to the precipitate and incubated
with shaking for 48 h. The protein precipitate was removed by
centrifugation and filtration, and the supernatant was used for
immunoblotting.
Immunoblotting. BS-C-1 cells were mock-infected or infected at
5 p.f.u. per cell for the indicated time and lysed in radioimmuno-
precipitation assay (RIPA) buffer. Protein samples were resolved by
SDS-PAGE, transferred to a nitrocellulose membrane and probed
with a-v-slfn polyclonal rabbit antiserum (1:100), rat monoclonal
antibody (mAb) 15B6 against the VACV F13 protein (1:100; Schmelz
et al., 1994), mouse a-FLAG M2 mAb (1:1000; Sigma-Aldrich) or
mouse a-HA mAb (1:1000; Covance). Secondary antibodies were
horseradish peroxidase (HRP)-conjugated goat anti-rabbit, anti-rat
and anti-mouse IgG (1:2000; Sigma-Aldrich). Bound Ab was
detected using Enhanced Chemiluminescence Plus Western blotting
detection reagents (Amersham Biosciences).
Immunofluorescence. HeLa cells were grown on sterile glass
coverslips (borosilicate glass; BDH) in six-well plates and intracellular
proteins were stained as described previously (Law et al., 2004).
Samples were examined with a Zeiss LSM 510 laser scanning confocal
microscope. Images were captured and processed using Zeiss LSM
Image Browser version 3.2. Primary Abs used were a-v-slfn polyclonal
antiserum (1:200) and a-HA mAb (1:500).
Construction of recombinant viruses. VACV vDB8R was used as
the parental virus for construction of recombinant VACV expressing
WT v-slfn, HA-tagged v-slfn or influenza virus HA from the TK locus.
CV-1 cells were infected with vDB8R at 0.1 p.f.u. per cell for 1 h and
then transfected with pMJ601, pMJ601-176RWT, pMJ601-176RNHA,
pMJ601-176RCHA or pMJ601-H1. Virus was harvested from infected
cells 3 days later and recombinant TK
2 viruses were selected by
growth on TK
2143 cells in the presence of 25 mg 5-bromodeoxy-
uridine (BUdR) ml
21 and chromogenic substrate X-Gal, as described
previously (Chakrabarti et al., 1985). Blue plaques were picked,
plaque purified and the presence of v-slfn was confirmed by PCR and
immunoblotting. Resulting viruses were named vDB8R, v176-WT,
v176-NHA, v176-CHA and vH1, respectively.
Mouse intradermal and intranasal model of infection. The
intradermal inoculations were carried out as described previously
(Tscharke & Smith, 1999). For the intranasal model, groups of female
BALB/c mice (6–8 weeks old) were infected intranasally with 4610
6
or 10
7 p.f.u. sucrose-purified virus in 20 ml PBS, and their weight and
signs of disease were scored daily as described previously (Alcami &
Smith, 1992). Mice infected with 4610
6 p.f.u. vH1, v176-WT or
v176-NHA were sacrificed at 3, 5 and 7 days post-infection (p.i.).
Cells present in the alveoli were removed by bronchoalveolar lavage
(BAL) using BAL solution (12 mM lidocaine and 5 mM EDTA in
Earl’s balanced salt solution), centrifuged at 800 g, resuspended in
erythrocyte lysis buffer (0.829% NH4Cl, 0.1% KHCO3, 0.0372%
Na2EDTA) for 3 min and kept on ice in RPMI/10% FBS. Lung cells
were obtained from lung homogenates by enzymic digestion, lysis of
erythrocytes and centrifugation through 20% Percoll (Sigma-
Aldrich), as described previously (Clark et al., 2006). Live cells in
BAL and lung single-cell suspensions were counted, blocked and
stained with appropriate combinations of fluorescein isothiocyanate-,
phycoerythrin- or tricolour-labelled a-CD25, a-CD69, a-CD3, a-CD8,
a-CD4, B220 or a-DX5 and the relevant isotype mAb controls (BD
Biosciences) as described previously (Clark et al., 2006). The distri-
bution of cell-surface markers was determined on a FACScan flow
cytometer with CellQUEST software (BD Biosciences). A lymphocyte
gate was used to analyse data from at least 20000 events. The titres of
virus in tissues were determined as described previously by plaque
assay on duplicate monolayers of TK
2143 cells (Reading & Smith,
2003).
Statistical analysis. Student’s t-test (two-tailed) was used to test the
significance of the results.
RESULTS
CMLV protein 176 (v-slfn) is related to members of
the slfn family
The characterization of murine slfn1 (m-slfn1), the
prototype of the slfn protein family, led to the identifica-
tion of related sequences in several OPVs (Schwarz et al.,
1998). Subsequent sequencing of CMLV identified another
v-slfn orthologue (protein 176, called v-slfn hereafter)
(Gubser & Smith, 2002). CMLV v-slfn was predicted to
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has 22% amino acid identity (approx. 41% similarity) to
an uncharacterized family of baculovirus proteins, collec-
tively known as p26 (Liu et al., 1986), and a C-terminal
domain related to the conserved region of m-slfns (Fig. 1).
v-slfn is poorly conserved amongst chordopoxviruses, with
only members of the OPV genus encoding putative v-slfn
counterparts; however, a p26-like domain is present in
certain entomopoxvirus proteins. Melanoplus sanguinipes
entomopoxvirus (MSEV) ORF 237 encodes a protein with
43% identity and 61% similarity to the first 197 aa of
CMLV v-slfn, although this sequence is absent in Amsacta
moorei entomopoxvirus (AMEV) (Afonso et al., 1999;
Bawden et al., 2000; Tulman et al., 2006).
Other OPVs predicted to encode full-length v-slfns are
CPXV, ectromelia virus (ECTV), monkeypox virus (MP-
XV) and taterapox virus (GBLV) (http://www.poxvirus.
org), whereas in VACV and VARV, the corresponding gene
is broken into fragments. All full-length OPV v-slfns share
between 84 and 100% amino acid identity (93–100%
amino acid similarity) with CMLV strain CMS v-slfn.
Fig. 1(a) shows a depiction of CMLV v-slfn protein and its
relationship with the v-slfn fragments from VACV strain
Western Reserve (WR) and a representative member of
each of the m-slfn subgroups. Altogether, CMLV v-slfn is
most similar to mammalian short m-slfns (m-slfn1 and 2),
lacking the C-terminal extensions of intermediate (m-slfn3
and 4) and long (m-slfn5, 8, 9, 10 and 14) m-slfns. Fig. 1(b)
shows an alignment of the conserved region of m-slfns with
the C terminus of v-slfn. In this region, v-slfn shares
between 24and 30% identity (42–60% similarity) with m-
slfns. Notably, v-slfn lacks similarity to the first 27 aa of m-
slfn1, which are essential for m-slfn1-mediated inhibition
of cell growth of fibroblasts (Fig. 1b; Geserick et al., 2004).
The unrooted tree in Fig. 1(c) shows the phylogenetic
relationships of OPV v-slfn proteins with their mammalian
counterparts. Due to their high sequence similarity, all
OPV v-slfns group closely together. Compared to mam-
malian counterparts, v-slfns are most closely related to
short m-slfns (m-slfn1 and 2) and least related to long m-
slfns (m-slfn5, 8, 9, 10 and 14), due to their lack of C-
terminal extension and also because of a lower degree of
similarity within the m-slfn conserved region (Fig. 1b).
Fig. 1(c) also highlights the reported divergence of m-slfn5
protein sequence (Geserick et al., 2004) and that of the
newly identified m-slfn14 (GenBank accession no. XP_
899217) to other long m-slfns.
Expression of v-slfn in fibroblasts
v-slfn is most similar to short m-slfns, of which m-slfn1
inhibits fibroblast cell growth in vitro (Schwarz et al., 1998;
Brady et al., 2005). To investigate whether v-slfn had a
similar effect on cell growth, a C-terminally FLAG-tagged
v-slfn was expressed stably in NIH3T3 cells using the T-
REx inducible system (Methods). Two independent clones
(clone B7; Fig. 2 and data not shown) were induced for
expression of v-slfn and after 24, 48 and 72 h the number
of viable cells was assessed (Fig. 2a). Although v-slfn was
expressed after addition of tetracycline (Fig. 2b, arrow),
there was no difference in cell proliferation between cells
that did or did not express v-slfn, showing that unlike
m-slfn1, but like intermediate long m-slfns (Schwarz et al.,
1998; Geserick et al., 2004; Brady et al., 2005), v-slfn does
not affect fibroblast cell growth in vitro.
Detection and characterization of v-slfn
To characterize v-slfn, the CMLV 176R gene was expressed
in E. coli with a C-terminal His tag, and the recombinant
protein was purified from inclusion bodies and used to
raise a rabbit a-v-slfn polyclonal Ab (Methods). In
immunoblots, the a-v-slfn Ab detected an approximately
57 kDa protein in cells infected with CMLV (Fig. 3a, b) or
with a recombinant VACV expressing CMLV v-slfn with or
without an HA tag (Fig. 3b, c). v-slfn was not present in
mock-infected cells.
The time of expression of the v-slfn protein during
infection was investigated in CMLV-infected cells
(Fig. 3a). v-slfn was expressed from 2 h p.i. and its
expression levels increased until 16 h p.i. The protein was
also detected at 16 h p.i. in cells in the presence of cytosine
arabinoside (AraC), an inhibitor of DNA replication and
thereby of virus intermediate and late gene expression,
indicating that v-slfn was expressed early during infection.
Fig. 2. v-slfn effect on NIH3T3 cell growth. (a) NIH3T3 cell line
(B7) expressing v-slfn stably upon tetracycline induction was
seeded at a density of 510
5 cells per 100 mm dish in triplicate
and, after 24 h, expression of v-slfn was induced or not by addition
of tetracycline (0.5 mgm l
”1). Cells were cultured over 72 h,
harvested by trypsinization and counted in duplicate. (b) Cell
lysates from (a) were analysed for expression of v-slfn using an a-
FLAG mAb (arrow). Data are representative of three independent
experiments. Positions of molecular size markers (kDa) are
indicated.
C. Gubser and others
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AraC indicates that the protein continues to be made after
DNA replication has started. In contrast, a 37 kDa protein,
which is the orthologue of VACV late protein F13, was not
expressed in the presence of AraC (Fig. 3a).
Sequence data predict that a v-slfn is expressed by some
OPVs; however, the v-slfn ORF is broken in sequenced
VACV and VARV strains (http://www.poxvirus.org). To
analyse whether other VACV and CPXV strains express a
full-length v-slfn, BS-C-1 cells were infected with 16 strains
of VACV and two strains of CPXV, and cell extracts were
analysed by immunoblotting (Fig. 3b). This showed that
none of the VACV strains examined expressed a protein
detected by the a-v-slfn Ab. However, in accord with
available sequence data, v-slfn was detected in cells infected
with CPXV strain Brighton Red (BR). Similarly, elephant-
pox virus (EP2), another CPXV strain, also expressed a
v-slfn counterpart. For both CPXV strains, the proteins
migrated slightly faster than CMLV v-slfn, despite having
a comparable predicted molecular mass (CPXV strain BR;
http://www.poxvirus.org). Both CPXV v-slfns were
detected at lower levels (Fig. 3b); however, this might be
due to a-v-slfn Ab specificity. The recognition of a 37 kDa
protein (VACV F13 orthologue) by an F13-specific mAb
confirmed that all cells had been infected (Fig. 3b, lower
panels). Note that the F13 orthologue in buffalopox virus
(BPXV)-infected cells was only detected at later times p.i.
(data not shown) and that a non-specific doublet is present
in mock-infected and infected cells. Thus, v-slfn is an early
and late protein that is encoded by a full-length ORF in
several OPVs, but is not expressed by any of the 16 VACV
strains tested, suggesting that it is either absent or broken
into smaller ORFs, as is the case for VACV strains
Copenhagen (COP) and WR.
Construction of recombinant VACV expressing
CMLV v-slfn
A VACV strain expressing full-length v-slfn was not
identified, therefore the function of v-slfn was studied
using a recombinant VACV expressing the CMLV v-slfn.
An attenuated VACV strain lacking the B8R gene encoding
the gamma interferon-binding protein (vDB8R) (Symons
et al., 2002) was selected as the parent virus to meet
biosafety concerns that insertion of the CMLV 176R gene
into VACV might increase virulence. In addition, the
CMLV 176R gene was inserted into the TK locus of vDB8R
to provide a second attenuating mutation (Buller et al.,
1985). v-slfn was expressed either without (v176-WT) or
with an N- or C-terminal HA tag (v176-NHA and v176-
CHA, respectively) under the control of a synthetic early
and late promoter. v-slfn expression by these viruses was
observed from 2 h p.i., similar to the expression pattern
seen in CMLV-infected cells (Fig. 3a and data not shown).
A control virus expressing the HA from influenza A/PR/8/
34 (Bennink et al., 1986) from the same locus and using the
same promoter was also constructed (vH1). The genotype
Fig. 3. Characterization of v-slfn by immunoblotting. (a) HeLa cells
were either mock-infected (M) or infected with CMLV strain CMS
at 5 p.f.u per cell and harvested when indicated. + indicates that
AraC was present throughout infection. Cell extracts were
analysed by immunoblotting using either a-v-slfn or a-F13 Abs.
(b) Expression of v-slfn protein in OPVs. Monolayers of BS-C-1
cells were mock-infected or infected with 5 p.f.u. of the indicated
virus per cell, harvested at 6 h p.i. and cell extracts were analysed
by immunoblotting using either a-v-slfn or a-F13 Abs. CMLV,
camelpox virus; VACV, vaccinia virus; WR, Western Reserve;
Patw, Patwadangar; King’s Ins, King’s Institute; Tashk, Tashkent;
COP, Copenhagen; CPXV, cowpox virus; EP2, elephantpox virus-
2; BPXV, buffalopox virus; RPXV, rabbitpox virus. (c) HeLa cells
were either mock-infected or infected with 10 p.f.u. of the
indicated VACV per cell, harvested 16 h p.i. and cell extracts
were analysed by immunoblotting. In all panels, the positions of
molecular size markers (kDa) are indicated.
Camelpox virus schlafen protein
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shown). HeLa cells were mock-infected or infected with
vDB8R, vH1, v176-WT, v176-NHA or v176-CHA, and
expression of v-slfn was detected using a-v-slfn Ab. Fig. 3(c)
shows that v176-WT, v176-CHA and v176-NHA express v-
slfn whereas, vDB8R and vH1 do not (top panel). Infection
was confirmed by detection of the VACV F13 orthologue in
all samples in parallel blots (Fig. 3c, bottom panel). The blots
were then stripped and reprobed with an a-HA mAb (Fig. 3c,
middle panel). This detected the HA-tagged protein
expressed by v176-CHA and 176-NHA. There was, however,
a reproducible large difference in level of detection between
the two samples, suggesting that the N terminus of N-
terminally tagged v-slfn is removed by proteolytic cleavage.
To determine whether expression of v-slfn altered virus
replication, the growth properties of vDB8R, vH1, v176-
WT, v176-NHA and v176-CHA were analysed. After
infection of BS-C-1 cells at 10 p.f.u. per cell for 24 or
48 h, the total virus yield of all recombinant viruses was
indistinguishable (Supplementary Fig. S1, available in JGV
Online). Similarly, VACV plaque morphology and size
were unaltered by expression of v-slfn in BS-C-1 (Supple-
mentary Fig. S2), RK13 and TK
2143 cells (data not shown).
Therefore, v-slfn does not affect virus growth or plaque size
when expressed by recombinant VACV under the condi-
tions tested.
Subcellular localization of v-slfn
To investigate the subcellular localization of v-slfn, HeLa
cells were either mock-infected or infected with CMLV
strain CMS, VACV WR or v176-CHA for 6 h (Fig. 4). v-slfn
was detected as a predominantly cytoplasmic protein with
no obvious localization to any organelles (Fig. 4c–e) and
similar localization was detected at later time points (data
not shown). No signal was present in mock-infected cells
(Fig. 4a), and only a weak background was present in cells
infected with VACV WR (Fig. 4b). The specificity of the v-
slfn antiserum was confirmed by co-staining cells infected
with v176-CHA with a-v-slfn Ab (Fig. 4d) and a-HA mAb
(Fig. 4e) and merging the images (Fig. 4f), showing co-
staining with these two Abs. v-slfn localization was also
analysed in NIH3T3 cell lines expressing v-slfn using an a-
FLAG mAb (data not shown), and after transient transfec-
tion of HeLa cells with the mammalian expression vector
pCI alone or pCI expressing v-slfn with or without an HA
tag. v-slfn was visualized with either a-v-slfn antiserum or a-
HA mAb. All approaches showed the same predominantly
cytoplasmic localization for v-slfn, ruling out the possibility
that other factors associated with virus infection contributed
to v-slfn localization (data not shown).
Expression of v-slfn attenuates VACV in the
murine intranasal model
The virulence of recombinant VACV that does or does not
express v-slfn was examined in the murine intradermal and
intranasal models of infection. In the intradermal model,
no difference in lesion size was observed between recom-
binant VACV expressing v-slfn or not (Supplementary
Fig. S3, available in JGV Online). In the murine intranasal
model of infection, mice infected with 10
7 p.f.u. vH1, v176-
WT, v176-NHA or v176-CHA all showed loss of body
weight (Fig. 5a, upper panel) and signs of illness (Fig. 5a
lower panel); however, from day 4 p.i. there was a
significant attenuation (P,0.05) of v176-WT and v176-
CHA compared with vH1 and v176-NHA. In addition,
mice infected with v176-WT or v176-CHA started to
recover sooner after infection (day 6, Fig. 5a) compared
with mice infected with vH1 and v176-NHA. This showed
that (i) expression of v-slfn attenuated VACV in this
model, and (ii) the function of v-slfn was affected by the
HA tag at the N terminus. The expression of the influenza
virus H1 HA from the TK locus did not alter VACV
virulence in this model (data not shown).
Fig. 4. Subcellular localization of v-slfn. HeLa cells were either (a)
mock-infected or infected with 5 p.f.u. per cell of (b) VACV WR, (c)
CMLV-CMS or (d–f) v176-CHA for 6 h and were analysed by
immunofluorescence using a-v-slfn (a–d) or a-HA (e) Abs. (f)
Shows a merged image of (d) and (e). Bars, 20 mm.
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VACV expressing an irrelevant protein (vH1) or non-
attenuating v-slfn (v-176NHA) were used as controls. Mice
were infected with 4610
6 p.f.u. vH1, v176-WT or v176-
NHA (Fig. 5b) and virus titres were measured in lungs
(Fig. 6a) and spleens (Fig. 6b) of infected animals. Initially,
all viruses replicated similarly in the lungs (day 3), but from
day 5 there was a reduction in virus titre after infection with
v176-WT, compared with v176-NHA and vH1. This differ-
ence was significant at day 7 p.i. for both control groups
(Fig. 6a). In the spleen, the v176R-WT titre was below the
level of detection at days 3 and 7 p.i., unlike vH1 and v176-
NHA, indicating that v176R-WT spread to this organ later
and was cleared earlier than control viruses (Fig. 6b).
The early clearance of virus after infection with v176-WT
compared with control groups suggested a more effective
antiviral host response, and therefore the cellular inflam-
matory response in lungs was analysed by flow cytometry
(Fig. 7). At days 3, 5 and 7 p.i., cells recovered from BALs
and lung cells from mice infected with v176-WT contained
an increased number of lymphoid cells compared with
mice infected with control viruses, and this difference was
significant at day 7 p.i. in BALs (Fig. 7a) and lungs (Fig. 7b).
To test whether this increase in lymphoid cells was due to
an enhanced recruitment of a particular lymphoid subset,
the percentage of CD4
+ and CD8
+ T lymphocytes, B220
+
B lymphocytes and DX5
+ natural killer (NK) cells present
in lungs was analysed, but no significant difference between
groups of mice was found (data not shown). Next, the
activation of CD3
+ T cells was investigated using the
activation marker CD69
+. This showed that although on
day 7 p.i. there were more lymphocytes recruited to lungs
infected with v-176WT compared with infection with vH1
or v176-NHA, CD3
+ T cells were less activated (Fig. 7c,
left panel), and this was reflected by a lower level of the
activation marker CD69
+ on both CD4
+ and CD8
+
lymphocytes (Fig. 7c, right panel). There was no difference
between groups in CD3
+ CD69
+ lymphocytes at days 3
and 5 p.i. (data not shown). Another activation marker,
Fig. 5. Virulence assay using the intranasal model of infection.
Groups of five BALB/c mice were mock-infected or infected with
(a) 10
7 or (b) 410
6 p.f.u. of the indicated purified viruses. Mice
were weighed daily, and results are the mean percentage weight
change of each group ± SEM compared to the weight on the day
of infection (upper panels). Animals were monitored daily for signs
of illness, scored 1 to 4 (Alcami & Smith, 1992) (lower panels).
Data are expressed as the mean ± SEM. P values were determined
using the Student’s t-test and indicate the meanpercentage
weight changes or signs of illness that were significantly different
between groups.
Fig. 6. Virus titres of vH1, v176-WT and v176-NHA in (a) lungs
and (b) spleens. Groups of five mice were infected intranasally with
410
6 p.f.u. of the indicated virus, and the lungs and spleen were
harvested at days 3, 5 and 7 p.i. Virus titres were determined by
plaque assay on TK
”143 cells. Virus titres are expressed as the
mean log10 p.f.u. per organ ± SEM. P values were determined
using Student’s t-test and indicate the mean virus titres that were
significantly different between mice infected with v176-WT and
mice infected with v176-NHA and vH1. Broken line indicates the
minimum detection limit of the plaque assay.
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+, was used in a further experiment and showed that
at days 7 and 10 p.i. there were also less CD25
+ CD4
+ and
CD25
+ CD8
+ lymphocytes in BALs of mice infected with
v-176WT compared with control groups, although this
difference was only significant for CD8
+ lymphocytes at
day 7 and CD4
+ lymphocytes at day 10 (Fig. 7d).
DISCUSSION
This paper provides a characterization of the CMLV-CMS
176R gene, which is shown to encode a predominantly
cytoplasmic 57 kDa protein that is expressed both early and
late in infection. v-slfn shows sequence similarity to the
mammalian schlafen protein family and is most closely
related to the short members, m-slfn1 and 2. Construction
of an inducible cell line that expresses v-slfn showed that,
unlike m-slfn1, v-slfn did not inhibit NIH3T3 cell growth.
This is probably due to v-slfn lacking a region with
sequence similarity to m-slfn1 aa 1–27 that is essential for
m-slfn1-mediated inhibition of fibroblast cell growth
(Geserick et al., 2004).
The m-slfn proteins are expressed differentially in activated
T cells and macrophages, and regulate T-cell development
and differentiation (Schwarz et al., 1998; Geserick et al.,
2004). Since there is no established small animal model for
studying CMLV pathogenesis, we screened several VACV
strains, hoping to identify a strain that expresses a full-
length v-slfn. However, none of the 16 strains examined
expressed a v-slfn orthologue suggesting that, like VACV
strain COP, the v-slfn ORF is broken into smaller fragment
in these viruses. Sequence data from VACV strains WR,
MVA and Lister are consistent with these observations.
Therefore, the function of v-slfn in vivo was investigated
using a recombinant VACV expressing untagged v-slfn
(v176WT) or v-slfn with a C-terminal (v176-CHA) or N-
terminal (v176-NHA) HA tag. Expression of WT or tagged
v-slfn by recombinant VACV did not affect virus virulence
in the intradermal model of infection. However, expression
of WT v-slfn or C-terminally tagged v-slfn attenuated
VACV in a murine intranasal model, resulting in reduced
weight loss and more rapid recovery compared with
control groups. In contrast, N-terminally tagged v-slfn
did not attenuate VACV in this model, showing that v-slfn
function was affected by addition of an HA tag on the N
terminus, and suggesting that this part of the protein is
important for function. The altered function of N-
terminally tagged v-slfn is possibly due to cleavage of a
small part of the N terminus of the protein after addition of
the HA tag, as shown by immunoblotting (Fig. 3c). v-slfn-
mediated attenuation in vivo was characterized by a
significantly reduced virus titre in lungs at day 7 p.i.
compared with vH1 and v-176NHA, although at day 3 the
titres were equivalent. This shows that expression of
v-slfn did not prevent establishment of infection or virus
replication, but probably accelerated virus clearance by the
immune system. Consistently, v176-WT spread to the
spleen was delayed and v176-WT was cleared more rapidly
from this organ compared with control groups.
Characterization of the cellular inflammatory response in
the lungs showed that v176-WT infection was characterized
by a more pronounced recruitment of lymphocytes that
was most striking at day 7 p.i. However, in lung cells, no
particular lymphoid subset (CD4
+ or CD8
+ T cells, B cells
or NK cells) was solely responsible for this increase. The
mechanism by which v-slfn promotes such vigorous
lymphocyte recruitment is under investigation. At day
7 p.i., when mice infected with v176-WT had almost
recovered, but mice infected with vH1 and v176-NHA were
Fig. 7. Analysis of cellular inflammatory response by flow cyto-
metry. (a, c and d) BAL and (b) lung cells were recovered on the
indicated day (a, b and d) or at day 7 (c) p.i. (a, b) Lymphoid
population was determined by its characteristic forward and side
scatter profiles. (c, d) Percentage of cells expressing activation
markers CD69
+ or CD25
+ in CD3
+, CD4
+ and CD8
+ cell
populations. Data shown are the mean percentage from five or six
mice ± SEM. P values were determined using Student’s t-test and
indicate the mean data that were significantly different between
mice infected with v176-WT, mice infected with v176-NHA and
mice infected with vH1. To obtain sufficient cells in BALs, cells
from two mice were pooled.
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+ lymphocytes present in the
BALs of mice infected with v176-WT showed a reduced
expression of activation markers CD69 and CD25, com-
pared with control groups. This was consistent with the
greater and earlier recruitment of lymphocytes, so that the
immune response was already declining by day 7.
It is unclear why a poxvirus would encode a protein that
decreases virus virulence. One possibility is to prevent the
virus from overwhelming its host too quickly. Another is
that the v-slfn protein affects virus virulence differently in
other models of infection and, consistent with this, v-slfn
did not affect virulence in the intradermal model (Supple-
mentary Fig. S3, available in JGV Online). VACV WR gene
B15R, which encodes a soluble interleukin-1b receptor, is
another example of a gene that decreases viral virulence in
one model but not others (Alcami & Smith, 1992, 1996;
Spriggs et al., 1992; Tscharke et al., 2002; Staib et al., 2005).
In summary, we have identified and characterized CMLV
strain CMS 176R and shown that it encodes an intracellular
protein, which attenuates VACV in vivo but does not affect
virus replication or plaque morphology in vitro. v-slfn
shares sequence similarity with members of the m-slfn
family of mammalian proteins, and recent reports suggest
that these play a role in the modulation of the innate and
adaptive immune responses against pathogens (Schwarz et
al., 1998; Eskra et al., 2003; Geserick et al., 2004). The exact
role of v-slfn within the context of a viral infection remains
to be elucidated.
ACKNOWLEDGEMENTS
This work was supported by grants from the Wellcome Trust. G.L.S.
is a Wellcome Trust Principal Research Fellow.
REFERENCES
Afonso, C. L., Tulman, E. R., Lu, Z., Oma, E., Kutish, G. F. & Rock, D. L.
(1999). The genome of Melanoplus sanguinipes entomopoxvirus. J
Virol 73, 533–552.
Afonso, C. L., Tulman, E. R., Lu, Z., Zsak, L., Sandybaev, N. T.,
Kerembekova, U. Z., Zaitsev, V. L., Kutish, G. F. & Rock, D. L. (2002).
The genome of camelpox virus. Virology 295, 1–9.
Alcami, A. & Smith, G. L. (1992). A soluble receptor for interleukin-1b
encoded by vaccinia virus: a novel mechanism of virus modulation of
the host response to infection. Cell 71, 153–167.
Alcami, A. & Smith, G. L. (1996). A mechanism for the inhibition of
fever by a virus. Proc Natl Acad Sci U S A 93, 11029–11034.
Bawden, A. L., Glassberg, K. J., Diggans, J., Shaw, R., Farmerie, W. &
Moyer, R. W. (2000). Complete genomic sequence of the Amsacta
moorei entomopoxvirus: analysis and comparison with other
poxviruses. Virology 274, 120–139.
Bennink, J. R., Yewdell, J. W., Smith, G. L. & Moss, B. (1986).
Recognition of cloned influenza virus hemagglutinin gene products
by cytotoxic T lymphocytes. J Virol 57, 786–791.
Brady, G., Boggan, L., Bowie, A. & O’Neill, L. A. (2005). Schlafen-1
causes a cell cycle arrest by inhibiting induction of cyclin D1. J Biol
Chem 280, 30723–30734.
Buller, R. M., Smith, G. L., Cremer, K., Notkins, A. L. & Moss, B.
(1985). Decreased virulence of recombinant vaccinia virus expression
vectors is associated with a thymidine kinase-negative phenotype.
Nature 317, 813–815.
Chakrabarti, S., Brechling, K. & Moss, B. (1985). Vaccinia virus
expression vector: coexpression of b-galactosidase provides visual
screening of recombinant virus plaques. Mol Cell Biol 5, 3403–3409.
Clark, R. H., Kenyon, J. C., Bartlett, N. W., Tscharke, D. C. & Smith,
G. L. (2006). Deletion of gene A41L enhances vaccinia virus
immunogenicity and vaccine efficacy. J Gen Virol 87, 29–38.
Davison, A. J. & Moss, B. (1990). New vaccinia virus recombination
plasmids incorporating a synthetic late promoter for high level
expression of foreign proteins. Nucleic Acids Res 18, 4285–4286.
Eskra, L., Mathison, A. & Splitter, G. (2003). Microarray analysis of
mRNA levels from RAW264.7 macrophages infected with Brucella
abortus. Infect Immun 71, 1125–1133.
Frickey, T. & Lupas, A. N. (2004). Phylogenetic analysis of AAA
proteins. J Struct Biol 146, 2–10.
Geserick, P., Kaiser, F., Klemm, U., Kaufmann, S. H. & Zerrahn, J.
(2004). Modulation of T cell development and activation by novel
members of the Schlafen (slfn) gene family harbouring an RNA
helicase-like motif. Int Immunol 16, 1535–1548.
Gubser, C. & Smith, G. L. (2002). The sequence of camelpox virus
shows it is most closely related to variola virus, the cause of smallpox.
J Gen Virol 83, 855–872.
Law, M., Hollinshead, M., Lee, H. J. & Smith, G. L. (2004). Yaba-like
disease virus protein Y144R, a member of the complement control
protein family, is present on enveloped virions that are associated
with virus-induced actin tails. J Gen Virol 85, 1279–1290.
Liu, A., Qin, J. C., Rankin, C., Hardin, S. E. & Weaver, R. F. (1986).
Nucleotide sequence of a portion of the Autographa californica
nuclear polyhedrosis virus genome containing the EcoRI site-rich
region (hr5) and an open reading frame just 59 of the p10 gene. J Gen
Virol 67, 2565–2570.
Lupas, A. N. & Martin, J. (2002). AAA proteins. Curr Opin Struct Biol
12, 746–753.
Moss, B. (2001). Poxviridae: the viruses and their replication. In Fields
Virology, 4th edn, pp. 2849–2883. Edited by D. M. Knipe & P. M.
Howley. Philadelphia, PA: Lippincott Williams & Wilkins.
Pires de Miranda, M., Reading, P. C., Tscharke, D. C., Murphy, B. J. &
Smith, G. L. (2003). The vaccinia virus kelch-like protein C2L affects
calcium-independent adhesion to the extracellular matrix and
inflammation in a murine intradermal model. J Gen Virol 84,
2459–2471.
Reading, P. C. & Smith, G. L. (2003). A kinetic analysis of immune
mediators in the lungs of mice infected with vaccinia virus and
comparison with intradermal infection. J Gen Virol 84, 1973–1983.
Schmelz, M., Sodeik, B., Ericsson, M., Wolffe, E. J., Shida, H., Hiller, G.
& Griffiths, G. (1994). Assembly of vaccinia virus: the second wrapping
cisterna is derived from the trans Golgi network. J Virol 68, 130–147.
Schwarz, D. A., Katayama, C. D. & Hedrick, S. M. (1998). Schlafen, a
new family of growth regulatory genes that affect thymocyte
development. Immunity 9, 657–668.
Smith, G. L., Levin, J. Z., Palese, P. & Moss, B. (1987). Synthesis and
cellular location of the ten influenza polypeptides individually
expressed by recombinant vaccinia viruses. Virology 160, 336–345.
Spriggs, M. K., Hruby, D. E., Maliszewski, C. R., Pickup, D. J., Sims,
J. E., Buller, R. M. & VanSlyke, J. (1992). Vaccinia and cowpox viruses
encodea novel secretedinterleukin-1-bindingprotein. Cell 71,1 4 5 – 1 5 2 .
Staib, C., Kisling, S., Erfle, V. & Sutter, G. (2005). Inactivation of the
viral interleukin 1b receptor improves CD8
+ T-cell memory
Camelpox virus schlafen protein
http://vir.sgmjournals.org 1675responses elicited upon immunization with modified vaccinia virus
Ankara. J Gen Virol 86, 1997–2006.
Symons, J. A., Tscharke, D. C., Price, N. & Smith, G. L. (2002). A
study of the vaccinia virus interferon-c receptor and its contribution
to virus virulence. J Gen Virol 83, 1953–1964.
Thompson, J. D., Higgins, D. G. & Gibson, T. J. (1994). CLUSTAL W:
improving the sensitivity of progressive multiple sequence alignment
through sequence weighting, position-specific gap penalties and
weight matrix choice. Nucleic Acids Res 22, 4673–4680.
Tscharke, D. C. & Smith, G. L. (1999). A model for vaccinia virus
pathogenesis and immunity based on intradermal injection of mouse
ear pinnae. J Gen Virol 80, 2751–2755.
Tscharke, D. C., Reading, P. C. & Smith, G. L. (2002). Dermal
infection with vaccinia virus reveals roles for virus proteins not seen
using other inoculation routes. J Gen Virol 83, 1977–1986.
Tulman, E. R., Delhon, G., Afonso, C. L., Lu, Z., Zsak, L., Sandybaev,
N. T., Kerembekova, U. Z., Zaitsev, V. L., Kutish, G. F. & Rock, D. L.
(2006). Genome of horsepox virus. J Virol 80, 9244–9258.
C. Gubser and others
1676 Journal of General Virology 88